Learning from Long-Term Antigen Changes in LF Patients
Mass drug administration (MDA) of Ivermectin and Albendazole has been a game-changer in the fight against lymphatic filariasis (LF). This strategy, part of the Global Programme to Eliminate Lymphatic Filariasis, has shown promising results. But how do we know when to stop? Researchers wante